Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047220 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4CYP4F2 | |
| SCHEMBL1043921 | 0.98 | TAAR1 (0.57) | TAAR1SLC6A3DRD2SLC6A4CYP4F2 | |
| SCHEMBL81108 | 0.92 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4CYP4F2 | |
| SCHEMBL2176833 | 0.86 | CYP4F2 (0.56) | CYP4F2CYP4A11BCHELPLLIPG | |
| SCHEMBL37877 | 0.84 | TAAR1 (0.63) | TAAR1SLC6A3DRD2SLC6A4CYP4F2 | |
| SCHEMBL238401 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11BCHELPLLIPG | |
| SCHEMBL7857344 | 0.82 | TAAR1 (0.62) | TAAR1SLC6A3DRD2SLC6A4NAAA | |
| SCHEMBL1046626 | 0.81 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4NAAA | |
| SCHEMBL4469226 | 0.81 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4NAAA | |
| SCHEMBL21453073 | 0.81 | LPL (0.62) | TAAR1SLC6A3DRD2SLC6A4LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090589-B2 | Specific nNOS inhibitors for the therapy and prevention of human melanoma | NORTHWESTERN UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-29 | — | — | US | disclosed |
| US-8642282-B2 | Inhibitors of nitric oxide synthase for treatment of melanoma | NORTHWESTERN UNIVERSITY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120238016-A1 | Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma | NORTHWESTERN UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2046746-A2 | CHEMICAL COMPOUNDS | Praecis Pharmaceuticals Incorporated (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | TAAR1 448/4885SLC6A3 2429/4885DRD2 1429/4885 |
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | NOS3, NOS1, NOS2 | TAAR1 2292/4885SLC6A3 1661/4885DRD2 4566/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | TAAR1 355/4885SLC6A3 4178/4885DRD2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.